Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference

Rhea-AI Summary

BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, a clinical-stage biopharmaceutical company, announced CEO Fred Guerard's participation at the Ophthalmology Innovation Summit (OIS) Retina on October 7, 2021, in San Antonio, Texas. He will present at the "Innovation Showcase" at 11:05 a.m. ET and participate in the "Finding and Funding Assets in Retina" panel at 4:55 p.m. ET. Graybug focuses on transformative medicines for retinal diseases, with its lead candidate, GB-102, targeting prolonged dosing regimens to improve treatment outcomes.

BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in the following events at the Ophthalmology Innovation Summit (OIS) Retina on Thursday, October 7, 2021, in San Antonio, Texas. The OIS Retina conference is being held in conjunction with the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting. Dr. Guerard will be a speaker at the following events:

• “Innovation Showcase” (company presentation)
  11:05 a.m. ET / 10:05 a.m. CT / 8:05 a.m. PT; and

• “Finding and Funding Assets in Retina” (panel discussion)
  4:55 p.m. ET / 3:55 p.m. CT / 1:55 p.m. PT
  

About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug’s lead product candidate, GB-102, a formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug’s other product candidates developed using its proprietary technologies also include GB-401, an injectable sustained-release formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug has offices in Redwood City, California and in Baltimore, Maryland. For more information, please visit www.graybug.vision.

Investor Contact IR@graybug.vision (650) 487-2409

Media Contact media@graybug.vision (404) 384-0067

FAQ

What is the date and location of the Ophthalmology Innovation Summit where Graybug Vision will participate?

The Ophthalmology Innovation Summit (OIS) Retina will take place on October 7, 2021, in San Antonio, Texas.

Who is speaking at the OIS Retina event for Graybug Vision?

Fred Guerard, CEO of Graybug Vision, will be speaking at the event.

What presentations will Fred Guerard give at the OIS Retina?

Fred Guerard will present at the "Innovation Showcase" at 11:05 a.m. ET and participate in a panel discussion titled "Finding and Funding Assets in Retina" at 4:55 p.m. ET.

What is Graybug's lead product candidate?

Graybug's lead product candidate is GB-102, designed for a sustained dosing regimen targeting retinal diseases.

What diseases does Graybug Vision focus on treating?

Graybug Vision focuses on developing treatments for diseases of the retina and optic nerve, including wet age-related macular degeneration.